These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 10442353)

  • 1. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
    Diasio RB
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral DPD-inhibitory fluoropyrimidine drugs.
    Diasio RB
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [5-fluorouracil and dihydropyrimidine dehydrogenase].
    Kubota T
    Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology.
    Diasio RB
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):21-6; discussion 27. PubMed ID: 11219973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
    Omura K
    Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.
    Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G
    Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral fluoropoyrimidines.
    Hoff PM; Royce M; Medgyesy D; Brito R; Pazdur R
    Semin Oncol; 1999 Dec; 26(6):640-6. PubMed ID: 10606257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-fluorouracil and dihydropyrimidine dehydrogenase.
    Kubota T
    Int J Clin Oncol; 2003 Jun; 8(3):127-31. PubMed ID: 12851835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving 5-FU with a novel dihydropyrimidine dehydrogenase inactivator.
    Diasio RB
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):51-6. PubMed ID: 9556784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents.
    Hoff PM; Pazdur R
    Semin Oncol; 1999 Dec; 26(6 Suppl 18):52-6. PubMed ID: 10892578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology.
    Diasio RB
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):23-7. PubMed ID: 9830621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
    Hoff PM
    Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
    Usuki H; Ishimura K; Yachida S; Hagiike M; Okano K; Izuishi K; Karasawa Y; Goda F; Maeta H
    Gastric Cancer; 2003; 6 Suppl 1():66-70. PubMed ID: 12775023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
    Schilsky RL; Kindler HL
    Expert Opin Investig Drugs; 2000 Jul; 9(7):1635-49. PubMed ID: 11060767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
    Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
    Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines].
    Gamelin E; Boisdron-Celle M; Morel A
    Therapie; 2007; 62(2):99-103. PubMed ID: 17582309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oral fluorinated pyrimidines.
    de Bono JS; Twelves CJ
    Invest New Drugs; 2001; 19(1):41-59. PubMed ID: 11291832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer.
    Inada T; Ogata Y; Kubota T; Tomikawa M; Yamamoto S; Andoh J; Ozawa I; Hishinuma S; Shimizu H; Kotake K
    Anticancer Res; 2000; 20(4):2457-62. PubMed ID: 10953310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans.
    Khor SP; Amyx H; Davis ST; Nelson D; Baccanari DP; Spector T
    Cancer Chemother Pharmacol; 1997; 39(3):233-8. PubMed ID: 8996526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
    Grem JL; Harold N; Shapiro J; Bi DQ; Quinn MG; Zentko S; Keith B; Hamilton JM; Monahan BP; Donavan S; Grollman F; Morrison G; Takimoto CH
    J Clin Oncol; 2000 Dec; 18(23):3952-63. PubMed ID: 11099325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.